MedTrace Logo

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2025-07-22

No results posted yet for this study

Summary

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Conditions

  • Prostatic Neoplasms, Castration-Resistant
  • Androgen-Resistant Prostatic Neoplasms
  • Castration Resistant Prostatic Neoplasms
  • Prostatic Cancer, Castration-Resistant

Interventions

DRUG

Etrumadenant

Etrumadenant is an A2aR and A2bR antagonist

DRUG

Zimberelimab

Zimberelimab is an anti-PD-1 antibody

DRUG

Quemliclustat

Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.

DRUG

Enzalutamide

Enzalutamide is an androgen receptor inhibitor

DRUG

Docetaxel

Docetaxel is type of chemotherapy

DRUG

SG

Sacituzumab govitecan is an antibody-drug conjugate

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2024-08-30
Completion
2024-08-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04381832 on ClinicalTrials.gov